Fluocinonide acetonide

Hawkins and Reifenrath made in vitro percutaneous absorption measurements using neat compoimds applied to skin and allowed to evaporate to air circulated over the apphed dose. For studies on benzo(a)pyrene absorption without sodium azide (NaNj), they foimd that mouse skin (6% of dose absorbed) was more permeable than human skin (1% of dose absorbed), which was more permeable than pig skin (0.6% of dose absorbed). In a similar study using 11 compounds [DDT, benzo(a)pyrene, fluocinonide acetonide, progesterone, hndane, testosterone, par-athion, diisopropyl fluorophosphonate, malathion, benzoic acid, and caffeine], they found that there was no statistically significant difference between human and pig skin. 

Novel secosteroids (336) and (337) have been prepared from the acid-catalysed rearrangements of fluocinonide acetonide (335 R = H) in the presence of trifluoro-methanesulfonic anhydride and trimethylsilyl trifluoromethanesulfonate as catalyst see... 

Compounds having the 16,17 ketal, eg, budesonide, amcinonide, fluocinonide, halcinonide, triamcinolone acetonide, and flurandrenohde, also undergo metabohsm by routes that parahel that of cortisol metabohsm. Unsymmetrical acetals such as budesonide are also metabolized by routes not available to the more metabohcahy stable symmetrical 16a,17a-isopropyhdiene-dioxysubstituted compounds (desonide, flunisohde, and triamcinolone acetonide). Isozymes within the cytochrome P450 3A subfamily are thought to catalyze the metabohsm of budesonide, resulting in formation of 16a-hydroxyprednisolone and 6P-hydroxybudesonide (19,20) (Fig. 3) in addition to the more common metabohc steps (oxidation via reduction of A, etc). 

A solution of 50 mg of 6a-fluoro-triamcinolone acetonide in 1 ml of pyridine and 1 ml of acetic anhydride is allowed to stand at room temperature for 18 hours. Removal of the reagents in vacuo gives a crystalline residue which after crystallization from acetone-hexane gives the pure 16a,17a-isopropylidene 6o -fluoro-triamcinolone 21 acetate (fluocinonide), as described in U.S. Patent 3,197,469. 

Alprenolol HCl Bromelain Ciprofibrate Clortermine HCl Desonide Fenofibrate Flucloronide Flunisolide Fluocinonide Flurandrenolide Glucagon Gramicidin Hetacillin potassium I proniazid Kebuzone Methyltestosterone Niaprazine Probucol Relaxin Somatotropin Triamcinolone acetonide Acetonitrile... 

Examples of group I, i.e. weak or low efficacy topical steroids, are hydrocortisone acetate in various concentrations, methylprednisolone 1.0% and prednisolone 0.5%. Group II, the moderately potent steroids, includes alclometasone dipropionate 0.05%, hydrocortisone butyrate 0.1%, triamcinolone acetonide 0.025% and fluocinolone ace-tonide 0.01%. Group III, the potent steroids, contains among others betamethasone valerate 0.1%, betamethasone dipropionate 0.05%, budesonide 0.025%, desoximetasone 0.05%, fluticasone propionate 0.05%, amcinonide 0.1%, fluocinonide 0.05% and mometasone furoate 0.1%. Group IV comprises the very potent agents such as clobetasol propionate 0.05% and halobetasol propionate 0.05%. 

Fluocinolone acetonide, 625 Fluocinolone acetonide acetate, 625 Fluocinonide, 625 Fluocortolone, 625 Fluocortolone caproate, 625 Fluocortolone hexanoate, 625 Fluocortolone pivalate, 625 Fluocortolone trimethylacetate, 625 Fluoderm, 625 Fluonid, 625 Fluopromazine, 626 Fluopromazine hyck ochloride, 626 Fluorandrenolone, 630 Fluorescein solution, 1169 Fluorescence detector, 203... 

The active component is the corticosteroid fluocinonide, which is the 21-acetate ester of fluocinolone acetonide. 

The ointment contains fluocinonide 0.5 mg/g in a specially formulated ointment base consisting of glyceryl monostearate, white petrolatum, propylene carbonate, propylene glycol, and white wax. It provides the occlusive and emollient effects desirable in an ointment. In this formulation, the active ingredient is totally in solution. In another formulation, the ointment contains fluocinolone acetonide 0.25 mg/g in a white petroleum USP vehicle. 

Simultaneous ciprocinonide, ftuocinolone acetonide, fluocinonide, procinonide... 

Additional mono- and difluorinated analogues for topical application include fluorometholone (6a-methyl-9a-fluoro ophthalmic use), flurandrenolide (6a-fluoro-16a,17a-acetonide), fluocinolone acetonide (a 6a, 9a-difluoro-16a,17a-acetonide), and fluocinonide (21-acetate ester of fluocinolone acetonide) (Fig. 33.13). These compounds are classified as high to medium potency anti-inflammatory agents depending on the concentration and vehicle used (Table 33.4). The acetonide (ketal) derivatives at the 16,17-position enhance lipophilicity to provide potent topical anti-inflammatory agents (Table 33.4). 

---